US Stock MarketDetailed Quotes

ANL Adlai Nortye

Watchlist
  • 3.640
  • +0.005+0.14%
Close Jul 3 13:00 ET
  • 3.470
  • -0.170-4.67%
Post 15:48 ET
134.32MMarket Cap-1279P/E (TTM)

About Adlai Nortye Company

Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Company Profile

SymbolANL
Company NameAdlai Nortye
Issue Price23.00
Founded2018
CEOMr. Yang Lu
MarketNASDAQ
Employees127
Securities TypeDR
ADS Ratio1.0 : 3.0
Fiscal Year Ends12-31
AddressBuilding 6 & 8,1008 Xiangwang Street,Yuhang District
CityHangzhou
ProvinceZhejiang
CountryChina
Zip Code311100
Phone86-571-289-8385
Websitehttp://www.adlainortye.com

Company Executives

  • Name
  • Position
  • Salary
  • Yang Lu
  • Chief Executive Officer and Chairman of the Board
  • --
  • Dr. Lars Erik Birgerson
  • Director, President and Chief Medical Officer; Chief Executive Officer, U.S. Subsidiary
  • --
  • Wei Vicky Zhang
  • Chief Financial Officer
  • --
  • Dr. Victoria Elizabeth Demby
  • Senior Vice President and Global Head, Regulatory Affairs
  • --
  • Dr. Kaiyang Tang
  • Senior Vice President and Global Head, Clinical Operations
  • --
  • Dr. Ping Ji
  • Director
  • --
  • Shaorong Liu
  • Independent Director
  • --
  • Ming Lun Alan Tse
  • Independent Director
  • --
  • Dr. Cheguo Cai
  • Independent Director
  • --
  • Dr. Archie Tse
  • Head of Research and Development
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg